LCG
KRYS icon

Lisanti Capital Growth’s Krystal Biotech KRYS Stock Holding History

Lisanti Capital Growth’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.08M Buy
19,050
+535
+3% +$160K 1.56% 12
2026
Q1 		$4.78M Buy
+18,515
New +$4.93M 1.21% 35
2025
Q2 		– Sell
-30,410
Closed -$5.48M – 124
2025
Q1 		$5.48M Buy
+30,410
New +$5.12M 1.63% 14
2023
Q3 		– Sell
-16,845
Closed -$1.98M – 147
2023
Q2 		$1.98M Buy
+16,845
New +$1.72M 0.27% 115

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lisanti Capital Growth's KRYS Position: Q2 2026 in Review

Lisanti Capital Growth increased its Krystal Biotech (KRYS) stake by 2.9% in Q2 2026, buying an estimated $160K and bringing the position to 19,050 shares worth $7.08M. The position accounts for 1.56% of the portfolio, ranked #12.

Lisanti Capital Growth first reported a position in KRYS in Q2 2023 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Lisanti Capital Growth held 19,050 shares of Krystal Biotech worth $7.08M as of Q2 2026.
  • Lisanti Capital Growth bought 535 Krystal Biotech shares in Q2 2026, an estimated $160K.
  • Krystal Biotech made up 1.56% of Lisanti Capital Growth's portfolio in Q2 2026, its #12 holding.
  • Lisanti Capital Growth first reported a position in Krystal Biotech in Q2 2023 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Lisanti Capital Growth's 13F filing for Q2 2026, filed 10 Aug 2026.